Ensuring safety of biosimilar low-molecular-weight heparins: A consensus statement of the International Union of Angiology

International Angiology

Volumn 31, Issue 2, 2012, Pages 101-104

  Harenberg, J ^a   Kalodiki, E ^a   Walenga, J M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ANGIOLOGY; CONFERENCE PAPER; DEPOLYMERIZATION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LOW DRUG DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; POSTMARKETING SURVEILLANCE;

ANIMALS; ANTICOAGULANTS; BIOSIMILAR PHARMACEUTICALS; BLOOD COAGULATION; DRUGS, GENERIC; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS;

EID: 84862228867     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. European Medicine Agency. Science Medicines Health. Concept paper on the revision of the guideline on nonclinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins [Internet]. Available at http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2011/07/WC500109588.pdf [cited 2012, Mar 2].
2. European Medicine Agency. Committee for Medicinal Products for Human Use. Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins [Internet]. Available at http://www.emea.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003927.pdf [cited 2012, Mar 2].
3. Harenberg J, Kakkar A, Bergqvist D, Barrowcliffe T, Casu B, Fareed J et al. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost 2009;7:1222-5.
4. Kalodiki E, Fareed J, Tapson VF, Hoppensteadt DA, Sussman I, Carter CA et al. A consensus conference on complex biologics and low molecular weight heparins. Int Angiol 2010;29:193-6.
5. WHO Guidelines on evaluation of Similar biotherapeutic products (SBPs), October 2009 [Internet]. Available at http://www.who.int/biologicals/areas/ biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf [cited 2012, Mar 2].
6. FDA US Food and Drug Administration. Establishing Active Ingredient Sameness for a Generic Enoxaparin Sodium, a Low Molecular Weight Heparin [Internet]. Available at http://www.fda.gov/Drugs/DrugSafety/Post- marketDrugSafetyInformationforPatientsandProviders/ucm220023.htm [cited 2012, Mar 2].
7. Ware JH, Hamel MB. Pragmatic trials-guides to better patient care? N Engl J Med 2011;364:1685-7.
8. Pinto VF. Non-inferiority versus equivalence clinical trials in assessing biological products. Sao Paulo Med J 2011;129:183-4.
9. Zuniga L, Calvo B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 2010;19:661-9.
10. Zuniga L, Calvo B. Regulatory aspects of biosimilars in Europe. Trends Biotechnol 2009;27:385-7.
11. Joung J, Robertson JS, Griffiths E, Knezevic I. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals 2008;36:269-76.
12. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005;25:954-62. (Pubitemid 40917928)
13. Malhotra H. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation. Biologicals 2011;39:321-4.
14. Hadavand N, Valadkhani M, Zarbakhsh A. Current regulatory and scientific considerations for approving biosimilars in Iran. Biologicals 2011;39:325-7.
15. Yamaguchi T, Arato T. Quality, safety and efficacy of follow-on biologics in Japan. Biologicals 2011;39:328-32.
16. Haddadin RD. Concept of biosimilar products in Jordan. Biologicals 2011;39:333-5.
17. Suh SK, Park Y. Regulatory guideline for biosimilar products in Korea. Biologicals 2011;39:336-8.
18. Abas A. Regulatory guidelines for biosimilars in Malaysia. Biologicals 2011;39:339-42.
19. Poh J, Tam KT. Registration of similar biological products-Singapore's approach. Biologicals 2011;39:343-5.
20. Thanaphollert P, Tungsanga K. Towards regulation of similar biotherapeutic products: Thailand's perspective. Biologicals 2011;39:346-7.
21. Bohlega S, Al-Shammri S, Al Sharoqi I, Dahdaleh M, Gebeily S, Inshasi J et al. Biosimilars: opinion of an expert panel in the Middle East. Curr Med Res Opin 2008;24:2897-903.